| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | CSF1R, CSFR, CD115, M-CSF-R |
| Product Type | |
| Shipping | |
| Species | |
| Storage |
Scientific Background
Colony Stimulating Factor 1 Receptor (CSF1R, CSFR, CD115, M-CSF-R) is a single-pass tyrosine kinase transmembrane receptor which is part of the type III protein tyrosine kinase receptor family. CSF1R is activated by either of two cytokines, CSF1 (MCSF; CSF-1) and IL-34 (IL34), causing homodimerization and activation of downstream kinase activity. CSF1R is expressed on the surface of monocytes and macrophages, and its activation controls the growth, function, and differentiation of macrophages. This interaction is used by numerous cancer types, such as diffuse-type tenosynovial giant cell tumors (dt-GCT), to evade the immune system. By overexpressing the cytokine CSF1, these cells drive the development and survival of Tumor-Associated Macrophages (TAMs), which in turn suppress the local immune response to the cancer. Activation of CSF1R by its ligand initiates a vast array of intracellular activity, including activation of the MAPK/ERK signaling pathway. When phosphorylated by ERK, Elk1 forms a complex with Serum Response Factor (SRF) and binds to Serum Response Element (SRE), resulting in the expression of numerous mitogen-inducible genes.
Product Description
KinaseThe CSF1R SRE HEK293 recombinant cell line has been transfected with full-length human CSF1R cDNA (NP_005202) under a CMV promoter for high constitutive expression. The SRE-luciferase reporter is also stably integrated into the genome. The firefly luciferase gene is controlled by 4 copies of the Serum Response Element upstream of a minimal promoter. Upon ligand binding, active CSF1R will initiate the MAPK/ERK signaling pathway, leading to expression of the SRE-controlled luciferase reporter.
Product Specifications
| Host Cell Line | HEK293 |
|---|---|
| Host Species | Human |
| Transfection Method | Lipofectamine 2000 |
| Supplied As | Two vials containing ~ 2 x 106 cells in 1 ml of 10% DMSO in FBS. |
| Harmonized Tariff Code | 3002-5900 |
Safety & Handling
⚠ Avoid multiple freeze/thaw cycles.
Regulatory Information
License Disclosure
Related Products
Related Products: Cat. #60690, 79617, 60187, 79723, 79796, 78487
Required Accessories: Cat. #60187,79723,79796,60690
This product is engineered on a HEK293 background (Human origin). The HEK293 host was selected for its compatibility with stable transfection and the target pathway or assay type. Consult the product datasheet for passage number guidance and recommended culture media.
This product is classified as BSL-2. Work must be performed in a certified BSL-2 laboratory by trained personnel. All procedures that may generate aerosols must be conducted inside a Class II Biological Safety Cabinet. Institutional Biosafety Committee (IBC) approval is required before use.
We recommend performing mycoplasma testing upon receipt and at regular intervals during culture, regardless of vendor QC status. Validated detection methods include PCR-based assays (e.g., Venor™GeM) and luminescence assays (e.g., MycoAlert™). Contamination can be introduced during routine handling.
Store this product at Liquid Nitrogen. Specifically: Store in liquid nitrogen immediately upon receipt. Do not store for long-term at -80°C or on dry ice. Transfer cells from dry-ice shipping to the recommended storage immediately upon receipt. Avoid repeated freeze-thaw cycles, which reduce viability and may alter expression characteristics.
Yes, a license is required (Yes). Purchase of this cell line grants a time-limited research-use license for use in your immediate laboratory only. This license does not permit redistribution, sub-licensing, transfer to other institutions, or commercial use. Refer to the License Disclosure section on this page or contact BPS Bioscience for details regarding modifications or commercial licensing.
This stable cell line was generated using Lipofectamine 2000 for transgene delivery into the parental host. The stably integrated cells were selected using the appropriate resistance marker and verified for expression prior to cryopreservation.
Can't find the cell line you need—or require a custom engineered model for your study? We offer end-to-end support for diverse research needs, including:
- Cell line sourcing and selection (species, tissue, and disease model matching)
- Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA)
- Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs)
- Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles)
- Inducible expression systems (Tet-On/Off and regulatable constructs)
- Drug resistance marker selection (puromycin, G418, hygromycin, and others)
- Custom growth and media optimisation for specific assay requirements
- Scale-up production for high-throughput screening campaigns
- Authentication and QC services (STR profiling, mycoplasma testing, viability assessment)
Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- Cannarile, Michael A., et al.
- “Colony-Stimulating Factor 1 Receptor (CSF1R) Inhibitors in Cancer Therapy.” Journal for Immunotherapy of Cancer, 5(1),(53), doi:10.1186/s40425-017-0257-y.
- Liu, Yang, and Xuetao Cao.
- “The Origin and Function of Tumor-Associated Macrophages.” Cellular and Molecular Immunology, 12(1), 1-4., doi:10.1038/cmi.2014.83.
- Luo, Jian, et al.
- “Colony-Stimulating Factor 1 Receptor (CSF1R) Signaling in Injured Neurons Facilitates Protection and Survival.” The Journal of Experimental Medicine, 210(1), 157-172., doi:10.1084/jem.20120412.
- Yao, G.-Q., et al.
- “CSF-1 Induces Fos Gene Transcription and Activates the Transcription Factor Elk-1 in Mature Osteoclasts.” Calcified Tissue International, 76(5), 371-378., doi:10.1007/s00223-004-0099-8.
